John McCarty, MD
Medical Oncology · Richmond, VANPI 1073603627
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $68,505 of the $97,345 with a category attached, or 70.4%. Gilead accounts for 77.7% of it on its own, with 11 other manufacturers making up the rest. Among medical oncology clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 79 payments — averaging $1232.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$76K
- Bristol Myers Squibb$15K
- Legend Biotech USA Inc.$3K
- National Marrow Donor Program$2K
- Jazz Pharmaceuticals Inc.$1K
- Incyte Corporation$246
- plus $508 from 6 others
Across 42 payments — averaging $7044.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$116K
- Gilead$101K
- National Marrow Donor Program$63K
- Janssen Research & Development, LLC$15K
- Seagen Inc.$188
What the payments were for
- Consulting fees$20,33521%
- Speaking & faculty fees$68,50570%
- Travel & lodging$4,8915%
- Food & beverage$3,5514%
- Education$640%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 46 | $75,650 |
| Bristol Myers Squibb | 13 | $14,927 |
| Legend Biotech USA Inc. | 1 | $2,805 |
| National Marrow Donor Program | 8 | $2,109 |
| Jazz Pharmaceuticals Inc. | 1 | $1,100 |
| Incyte Corporation | 2 | $246 |
| Novartis | 2 | $151 |
| E.r. Squibb & Sons, L.L.C. | 2 | $128 |
| Seagen Inc. | 1 | $80 |
| Iovance Biotherapeutics, Inc. | 1 | $65 |
| AstraZeneca | 1 | $43 |
| Genetix Biotherapeutics Inc | 1 | $42 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$97,345 in reported general payments places this provider in the 90th percentile of 95 medical oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 15 | $299,206 |
| Acyclovir | 16 | $412 |
| Pantoprazole Sodium | 11 | $168 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Richmond
- Keri MaherRichmond$96K
- Khalid MatinRichmond$16K
- Janakiraman SubramanianFairfax$562K
- Alexander SpiraFairfax$533K
- Robert DreicerCharlottesville$296K
- Roy BeveridgeFairfax$216K
- Kathleen HarndenFairfax$195K
- Jeanny Aragon-ChingFalls Church$194K
- Nagla Abdel KarimFairfax$131K
- Ryan GentzlerCharlottesville$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.